Arcutis Biotherapeutics (ARQT) Free Cash Flow (2019 - 2026)

Arcutis Biotherapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 106.72% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $26.8 million (up 123.96% YoY), while the FY2025 annual figure was -$6.3 million, up 94.38% from the prior year.
• Free Cash Flow for Q1 2026 stood at $2.1 million, down from $26.2 million in the prior quarter.
• The five-year high for Free Cash Flow was $26.2 million in Q4 2025, with the low at -$80.4 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$44.0 million (2023), against an average of -$36.6 million.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow tumbled 72.99% in 2022, then surged 3600.67% in 2025.
• Arcutis Biotherapeutics' Free Cash Flow stood at -$71.2 million in 2022, then climbed by 20.98% to -$56.2 million in 2023, then jumped by 98.67% to -$748000.0 in 2024, then soared by 3600.67% to $26.2 million in 2025, then slumped by 92.05% to $2.1 million in 2026.
• Business Quant data shows ARQT's Free Cash Flow at $2.1 million in Q1 2026, $26.2 million in Q4 2025, and -$1.8 million in Q3 2025.